View Filing Data

Print Document View Excel Document

Document And Entity Information - shares	9 Months Ended
Document And Entity Information - shares	Sep. 30, 2012	Nov. 09, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	Celsion CORP
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		35,012,924
Amendment Flag	false
Entity Central Index Key	0000749647
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Sep. 30, 2012
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	Q3

Balance Sheets (Current Period Unaudited) - USD ($)	Sep. 30, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 8,318,336	$ 20,145,854
Investment securities – available for sale, at fair value	14,229,181	10,157,160
Accrued interest receivable on investment securities	133,552	243,745
Advances and deposits for investigator grants	807,795	758,297
Vendor reimbursements receivable	173,598
Other current assets	103,728	203,429
Total current assets	23,766,190	31,508,485
Property and equipment (at cost, less accumulated depreciation of $799,712 and $643,472, respectively)	1,007,590	782,720
Other assets:
Deposits, deferred fees and other assets	605,372	322,629
Patent licensing fees, net	30,000	35,625
Total other assets	635,372	358,254
Total assets	25,409,152	32,649,459
Current liabilities:
Accounts payable	2,944,956	4,010,203
Accrued liabilities	2,715,509	2,031,934
Notes payable - current portion	945,433	110,287
Total current liabilities	6,605,898	6,152,424
Common stock warrant liability	1,417,248	166,398
Notes payable – non-current portion	4,140,186	71,602
Other non-current liabilities	221,832	65,467
Total liabilities	12,385,164	6,455,891
Stockholders' equity:
Common stock, $0.01 par value; 75,000,000 shares authorized and 35,459,494 and 33,899,057 shares issued at September 30, 2012 and December 31, 2011 and 34,792,207 and 33,186,325 shares outstanding at September 30, 2012 and December 31, 2011, respectively	354,595	338,991
Additional paid-in capital	158,121,079	153,237,225
Accumulated other comprehensive loss	(131,306)	(276,700)
Accumulated deficit	(142,620,295)	(124,221,823)
Subtotal	15,724,073	29,077,693
Treasury stock, at cost (667,287 and 712,732 shares at September 30, 2012 and December 31, 2011, respectively)	(2,700,085)	(2,884,125)
Total stockholders' equity	13,023,988	26,193,568
Total liabilities and stockholders' equity	$ 25,409,152	$ 32,649,459

Balance Sheets (Current Period Unaudited) (Parentheticals) - USD ($)	Sep. 30, 2012	Dec. 31, 2011
Accumulated Depreciation (in Dollars)	$ 799,712	$ 643,472
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in Shares)	75,000,000	75,000,000
Common stock, shares issued (in Shares)	35,459,494	33,899,057
Common stock, shares outstanding (in Shares)	34,792,207	33,186,325
Treasury stock, shares (in Shares)	667,287	712,732

- Definition

The cumulative amount of depreciation, depletion and amortization (related to property, plant and equipment, but not including land) that has been recognized in the income statement.

+ References + Details

Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
Statements of Operations (Unaudited) - USD ($)	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Licensing revenue				$ 2,000,000
Operating expenses:
Research and development	$ 3,539,309	$ 5,414,284	$ 12,344,559	14,726,942
General and administrative	1,420,258	1,408,828	4,586,005	3,906,095
Total operating expenses	4,959,567	6,823,112	16,930,564	18,633,037
Loss from operations	(4,959,567)	(6,823,112)	(16,930,564)	(16,633,037)
Other (expense) income:
(Loss) gain from valuation of common stock warrant liability	(881,127)	375,378	(1,250,850)	(42,482)
Investment (loss) income, net	(5,581)	26,347	61,828	26,911
Interest and dividend expense	(171,720)	(13,710)	(187,995)	(494,797)
Other income (expense)		42,145	(1,040)	42,145
Total other (expense) income, net	(1,058,428)	430,160	(1,378,057)	(468,223)
Net Loss	$ (6,017,995)	$ (6,392,952)	$ (18,308,621)	$ (17,101,260)
Net loss per common share – basic and diluted (in Dollars per share)	$ (0.18)	$ (0.25)	$ (0.55)	$ (0.93)
Weighted average shares outstanding – basic and diluted (in Shares)	33,641,810	25,150,084	33,412,822	18,360,149

Statements of Comprehensive Loss (unaudited) - USD ($)	3 Months Ended		9 Months Ended
Statements of Comprehensive Loss (unaudited) - USD ($)	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Net Loss	$ (6,017,995)	$ (6,392,952)	$ (18,308,621)	$ (17,101,260)
Other comprehensive gain (loss)
Unrealized gain (loss) on investment securities	184,294	(178,681)	145,394	(138,763)
Comprehensive loss	$ (5,833,701)	$ (6,571,633)	$ (18,163,227)	$ (17,240,023)

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the economic entity, including both controlling (parent) and noncontrolling interests. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, including any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

- Definition

Net of tax amount of unrealized holding gain (loss) before reclassification adjustments and transfers on available-for-sale securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 10A
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=20435746&loc=SL7669646-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e637-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 17, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 24
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph c(3)
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
Statements of Cash Flows (Unaudited) - USD ($)	Sep. 30, 2012	Sep. 30, 2011
Cash flows from operating activities:
Net loss	$ (18,308,621)	$ (17,101,260)
Non-cash items included in net loss:
Depreciation and amortization	161,865	129,735
Change in fair value of common stock warrant liability	1,250,850	42,482
Stock-based compensation	850,990	892,894
Treasury shares issued for services and 401(k) matching contribution	94,189	116,188
Change in deferred rent liability	59,085
Net changes in:
Accrued interest on short term investments and other current assets	9,897	(259,666)
Accounts payable	(967,967)	(1,775,932)
Other accrued liabilities	683,575	(347,422)
Net cash used in operating activities:	(16,166,137)	(18,302,981)
Cash flows from investing activities:
Purchases of investment securities	(16,213,657)	(10,415,493)
Proceeds from sale and maturity of investment securities	12,287,030	395,556
Security deposit on letter of credit		(250,000)
Purchases of property and equipment	(381,110)	(328,866)
Net cash used in investing activities	(4,307,737)	(10,598,803)
Cash flows from financing activities:
Proceeds from sale of 8% Series A Redeemable, Convertible Preferred Stock, net of issuance costs		4,324,080
Proceeds from sale of common stock equity, net of issuance costs		34,268,411
Proceeds from notes payable	4,814,398
Proceeds from exercise of common stock warrants	3,823,690	394,336
Proceeds from exercise of options to purchase common stock	104,538
Principal payments on notes payable	(96,270)	(91,069)
Net cash provided by financing activities	8,646,356	38,895,758
(Decrease) increase in cash and cash equivalents	(11,827,518)	9,993,974
Cash and cash equivalents at beginning of period	20,145,854	1,138,916
Cash and cash equivalents at end of period	8,318,336	11,132,890
Supplemental disclosures of cash flow information:
Interest and preferred stock dividends paid	$ 187,995	$ 481,087

Note 1. Business Description

6 Months Ended

Jun. 30, 2012

Nature of Operations [Text Block]

Note 1. Business Description

Celsion Corporation, referred to herein as “Celsion”, “We”, or “the Company,” a Delaware corporation based in Lawrenceville, New Jersey, is an innovative oncology drug development company focused on improving treatment for those suffering with difficult-to-treat forms of cancer. We are working to develop and commercialize more efficient, effective, targeted chemotherapeutic oncology drugs based on our proprietary heat-activated liposomal technology. Our lead product ThermoDox® is being tested in human clinical trials for the treatment of primary liver cancer, recurrent chest wall breast cancer and colorectal liver metastases.

Note 2. Basis of Presentation

9 Months Ended

Sep. 30, 2012

Basis of Presentation and Significant Accounting Policies [Text Block]

Note 2. Basis of Presentation

The accompanying unaudited financial statements of Celsion have been prepared in accordance with generally accepted accounting principles (GAAP) in the United States for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations.

In the opinion of management, all adjustments, consisting only of normal recurring accruals considered necessary for a fair presentation, have been included in the accompanying unaudited financial statements. Operating results for the three and nine month periods ended September 30, 2012 are not necessarily indicative of the results that may be expected for any other interim period(s) or for any full year. For further information, refer to the financial statements and notes thereto included in the Company’s Annual Report on Form 10-K/A for the fiscal year ended December 31, 2011 filed with the Securities and Exchange Commission on March 15, 2012.

The preparation of financial statements in conformity with GAAP requires management to make judgments, estimates, and assumptions that affect the amount reported in the Company’s financial statements and accompanying notes. Actual results could differ materially from those estimates.

Events and conditions arising subsequent to the most recent balance sheet date have been evaluated for their possible impact on the financial statements and accompanying notes. No events and conditions would give rise to any information that required accounting recognition or disclosure in the financial statements other then those arising in the ordinary course of business.

Certain items in the prior period financial statements have been reclassified to conform to the current period presentation.

Note 3. New Accounting Pronouncements

9 Months Ended

Sep. 30, 2012

Description of New Accounting Pronouncements Not yet Adopted [Text Block]

Note 3. New Accounting Pronouncements

From time to time, new accounting pronouncements are issued by FASB and are adopted by us as of the specified effective date. Unless otherwise discussed, we believe that the impact of recently issued accounting pronouncements will not have a material impact on the Company’s consolidated financial position, results of operations, and cash flows, or do not apply to our operations.

In June 2011, the Financial Accounting Standards Board (FASB) amended its guidance on the presentation of comprehensive income in financial statements to improve the comparability, consistency and transparency of financial reporting and to increase the prominence of items that are recorded in other comprehensive income. The new accounting guidance requires entities to report components of comprehensive income in either (1) a continuous statement of comprehensive income or (2) two separate but consecutive statements. The provisions of this new guidance are effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. We have incorporated this guidance into these financial statements and they did not have a material impact on the Company's financial statements.

There were no new accounting pronouncements issued or effective during the first nine months of 2012 that have had or are expected to have a material impact on the Company’s financial statements.

Note 4. Net Loss Per Common Share

9 Months Ended

Sep. 30, 2012

Earnings Per Share [Text Block]

Note 4. Net Loss per Common Share

Basic earnings per share is calculated based upon the net loss available to common shareholders divided by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated after adjusting the denominator of the basic earnings per share computation for the effects of all dilutive potential common shares outstanding during the period. The dilutive effects of options, warrants and their equivalents are computed using the treasury stock method.

For the three and nine months ended September 30, 2012 and 2011, diluted loss per common share was the same as basic loss per common share as all options and warrants that were convertible into shares of the Company’s common stock were excluded from the calculation of diluted earnings per share as their effect would have been anti-dilutive. The total number of outstanding warrants and equity awards for the three and nine month periods ended September 30, 2012 and 2011 were 13,643,404 and 11,492,716 common stock equivalent shares, respectively.

Note 5. Investment Securities - Available For Sale

9 Months Ended

Sep. 30, 2012

Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]

Note 5. Investment Securities - Available For Sale

Investment securities available for sale of $14,229,181 and $10,157,160 as of September 30, 2012 and December 31, 2011, respectively, consist of commercial paper, corporate debt securities and equity securities. They are valued at fair value, with unrealized gains and losses reported as a separate component of stockholders’ equity in Accumulated Other Comprehensive Loss.

Investment securities available for sale are evaluated periodically to determine whether a decline in their value is other than temporary. The term “other than temporary” is not intended to indicate a permanent decline in value. Rather, it means that the prospects for near-term recovery of value are not necessarily favorable, or that there is a lack of evidence to support fair values equal to, or greater than, the carrying value of the security. Management reviews criteria such as the magnitude and duration of the decline, as well as the reasons for the decline, to predict whether the loss in value is other than temporary. Once a decline in value is determined to be other than temporary, the value of the security is reduced and a corresponding charge to earnings is recognized.

Investment securities - available for sale - at fair value	September 30, 2012		December 31, 2011

Bonds - corporate issuances	$	14,091,590	$	10,157,160
Equity securities		137,591		–
Total short-term investments, available for sale	$	14,229,181	$	10,157,160

A summary of the cost, fair value and bond maturities of the Company’s investment securities is as follows:

	September 30, 2012				December 31, 2011
	Cost		Fair Value		Cost		Fair Value
Short-term investments
Bonds- corporate issuances	$	14,252,114	$	14,091,590	$	10,325,487	$	10,157,160
Equity securities		108,373		137,591		108,373		–
Total	$	14,360,487	$	14,229,181	$	10,433,860	$	10,157,160

Bond maturities
Within 3 months	$	6,084,600	$	6,010,500	$	5,128,560	$	5,036,920
Between 3-12 months		8,167,514		8,081,090		5,196,927		5,120,240
Total	$	14,252,114	$	14,091,590	$	10,325,487	$	10,157,160

The following table shows the Company’s investment securities gross unrealized losses and fair value by investment category and length of time that individual securities have been in a continuous unrealized loss position at September 30, 2012 and December 31, 2011. The Company has reviewed individual securities to determine whether a decline in fair value below the amortizable cost basis is other then temporary.

	September 30, 2012
	Less than 12 months					12 months or Longer				Total
Description of Securities	Fair Value		Gross Unrealized Holding Losses			Fair Value		Gross Unrealized Holding Gains		Fair Value		Gross Unrealized Holding (Losses) Gains

Available for Sale
Bonds – corporate issuances	$	14,091,590	$	(160,524	)	$	–	$	–	$	14,091,590	$	(160,524	)
Equity securities		–		–			137,591		29,218		137,591		29,218
	$	14,091,590	$	(160,524	)	$	137,591	$	29,218	$	14,229,181	$	(131,306	)

	December 31, 2011
	Less than 12 months					12 months or Longer					Total
	Fair Value		Gross Unrealized Holding Losses			Fair Value		Gross Unrealized Holding Losses			Fair Value		Gross Unrealized Holding Losses
Available for Sale
Bonds – corporate issuances	$	10,157,160	$	(168,327	)	$	–	$	–		$	10,157,160	$	(168,327	)
Equity securities		–		(93,924	)		–		(14,449	)		–		(108,373	)
	$	10,157,160	$	(262,251	)	$	–	$	(14,449	)	$	10,157,160	$	(276,700	)

Gross realized gains and losses on sales of available for sale securities and investment income, which includes interest and dividends, is summarized as follows:

	Three Months Ended September 30,					Nine Months Ended September 30,
	2012			2011		2012				2011
Interest and dividend income	$	115,449		$	26,347		$	380,034			$	26,911
Realized losses		(121,030	)		–			(318,206	)			–
	$	(5,581	)	$	26,347		$	61,828			$	26,911

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-Glossary Debt Security
-URI http://asc.fasb.org/extlink&oid=6509901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-Glossary Equity Security
-URI http://asc.fasb.org/extlink&oid=6511694

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27232-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27161-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27405-111563

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 3, 19, 20, 21, 22, 137
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Note 6. Fair Value of Measurements

9 Months Ended

Sep. 30, 2012

Fair Value Disclosures [Text Block]

Note 6. Fair Value of Measurements

FASB Accounting Standards Codification (ASC) Section 820 (formerly SFAS No. 157) “Fair Value Measurements and Disclosures,” establishes a three level hierarchy for fair value measurements which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The three levels of inputs that may be used to measure fair value are as follows:

Level 1: Quoted prices (unadjusted) or identical assets or liabilities in active markets that the entity has the ability to access as of the measurement date;

Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data; and

Level 3: Significant unobservable inputs that reflect a reporting entity’s own assumptions that market participants would use in pricing an asset or liability.

The fair values of securities available for sale are determined by obtaining quoted prices on nationally recognized exchanges (Level 1 inputs) or matrix pricing, which is a mathematical technique widely used in the industry to value debt securities without relying exclusively on quoted prices for the specific securities but rather by relying on the securities’ relationship to other benchmark quoted securities (Level 2 inputs). The common stock warrant liability has been valued using the Black-Scholes option pricing model, the inputs of which are more fully described in Note 11 to the financial statements.

Cash and cash equivalents, other current assets, accounts payable and other accrued liabilities are reflected in the balance sheet at their estimated fair values primarily due to their short-term nature.

The following table presents information about assets and liabilities recorded at fair value on a recurring basis as of September 30, 2012 and December 31, 2011 on the Company’s Balance Sheet:

	Total Fair Value on the Balance Sheet		Quoted Prices In Active Markets For Identical Assets/Liabilities(Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
As of September 30, 2012
Short-term investments available for sale
Bonds – corporate issuances	$	14,091,590	$	14,091,590	$	−	$	−
Equity Securities		137,591		–		–		137,591

As of December 31, 2011
Short-term investments available for sale
Bonds – corporate issuances	$	10,157,160	$	10,157,160	$	−	$	−
Equity Securities		–		–		–		–

Liabilities:
As of September 30, 2012
Common stock warrant liability	$	1,417,248	$	−	$	−	$	1,417,248

As of December 31, 2011
Common stock warrant liability	$	166,398	$	−	$	−	$	166,398

There were no transfers of assets or liabilities between Level 1 and Level 2 and no transfers in or out of Level 3 during the nine month period ended September 30, 2012.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Note 7. Other Accrued Liabilities

9 Months Ended

Sep. 30, 2012

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Note 7. Other Accrued Liabilities

Accrued liabilities at September 30, 2012 and December 31, 2011 include the following:

	September 30, 2012		December 31, 2011
Amounts due to Contract Research Organizations and other contractual agreements	$	2,256,514	$	1,234,875
Accrued payroll and related benefits		322,713		632,425
Accrued professional fees		108,653		137,400
Other		27,629		27,234
Total	$	2,715,509	$	2,031,934

Note 8. Note Payable

9 Months Ended

Sep. 30, 2012

Debt Disclosure [Text Block]

Note 8. Note Payable

On June 27, 2012, the Company entered into a Loan and Security Agreement (the “Credit Agreement”) with Oxford Finance LLC (“Oxford”) and Horizon Technology Finance Corporation (“Horizon”). The Credit Agreement provides for a secured term loan of up to $10 million, with 50% of any loans to be funded by Oxford and 50% to be funded by Horizon. The aggregate loan amount may be advanced in two tranches of $5 million each. The first tranche (the “Term A Loan”) was made available to the Company on June 27, 2012 and the second tranche (the “Term B Loan”) may be made available, if at all, during the period beginning on the date that the Company achieves positive data in its Phase III clinical trial of RFA and ThermoDox® (the HEAT Study) and ending on March 31, 2013. The Term A Loan is scheduled to mature on October 15, 2015 (or, if the Term B Loan is made available, January 1, 2016) and the Term B Loan is scheduled to mature on January 1, 2016. The proceeds of the Credit Agreement will be used to fund the Company’s working capital and general corporate purposes. The obligations under the Credit Agreement are secured by substantially all assets of the Company other than its intellectual property and certain other agreed-upon exclusions.

The Term A Loan bears interest at a fixed rate of 11.75%. If it is made available, the Term B Loan will bear interest at a fixed rate equal to the greater of (i) 11.75% or (ii) the sum of (a) the three month U.S. LIBOR rate (but not less than 0.47%) three days prior to the funding of the loan plus (b) 11.28%. Generally, the Company is required to pay principal and interest in equal monthly installments. However for an initial period extending for the Term A Loan through May 1, 2013 (or, if the Term B Loan is made available, January 1, 2016) and for the Term B Loan through August 1, 2013, the Company is only required to make interest payments. The Company is also obligated to pay other customary facility fees for a credit facility of this size and type.

The Credit Agreement contains customary covenants, including covenants that limit or restrict the Company’s ability to incur liens, incur indebtedness, make certain restricted payments, merge or consolidate and make dispositions of assets. Upon the occurrence of an event of default under the Credit Agreement, the lenders may cease making loans, terminate the Credit Agreement, declare all amounts outstanding to be immediately due and payable and foreclose on or liquidate the Company’s assets that comprise the lenders’ collateral. The Credit Agreement specifies a number of events of default (some of which are subject to applicable grace or cure periods), including, among other things, non-payment defaults, covenant defaults, a material adverse change in the Company, cross-defaults to other materials indebtedness, bankruptcy and insolvency defaults and material judgment defaults. The Company is currently in compliance with these covenants.

As a fee in connection with the Credit Agreement, the Company issued warrants to Horizon and Oxford (the “Warrants”) to purchase the number of shares of the Company’s common stock equal to 3% of each loan amount divided by the exercise price, which was calculated as the average NASDAQ closing price of The Company common stock for the three days prior to the funding of the loan amount ($2.92 per share for the Term A Loan). This resulted in 51,370 warrant shares issued in connection with the Term A Loan and additional warrant shares issuable in connection with the Term B Loan, if that is made available. The Warrants issued in connection with the Term A Loan are immediately exercisable for cash or by net exercise and will expire seven years after their issuance, which is June 27, 2019.

The Company valued the Warrants using the Black-Scholes option pricing model and recorded $73,654 as deferred financing fees. In calculating the value of the warrants, the Company assumed a volatility rate of 74.3%, risk free interest rate of 1.10%, an expected life of 3.5 years, a stock price of $2.80 (closing price on date of the Warrant) and no expected forfeitures nor dividends. In connection with the Credit Agreement, the Company incurred cash expenses of $207,207 which were recorded as deferred financing fees. These deferred financing fees will be amortized as interest expense over the life of the loan.

For the period since the Credit Agreement’s inception through September 30, 2012, $21,605 in deferred financing fees were amortized as interest expense. Also, the Company paid $146,875 in interest expense on the Credit facility during this same period.

Following is a schedule of future principle payments due on the Credit Agreement:

	Credit Agreement
For the year ending September 30:
2013	$	886,616
2014		1,936,586
2015		2,176,798
	$	5,000,000

In October 2009, the Company financed $288,200 of lab equipment through a capital lease. This lease obligation had thirty monthly payments of $11,654 through April 2012. During the first half of 2012, the Company has made principal and interest payments totaling $58,270. The lease obligation was paid in full during the second quarter of 2012.

In November 2011, the Company financed $144,448 of lab equipment through a capital lease. This lease obligation has thirty monthly payments of $5,651 through February 2014. During the first nine months of 2012, the Company made principal and interest payments totaling $50,863. The outstanding lease obligation is $85,618 as of September 30, 2012.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References + Details

Note 9. Stock Based Compensation

9 Months Ended

Sep. 30, 2012

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

Note 9. Stock Based Compensation

Stock Options Plans

The Company has long-term compensation plans that permit the granting of incentive awards in the form of stock options. Generally, the terms of these plans require that the exercise price of the options may not be less than the fair market value of Celsion’s common stock on the date the options are granted. Options granted generally vest over various time frames or upon milestone accomplishments. The Company’s options generally expire ten years from the date of the grant.

In 2007, the Company adopted the Celsion Corporation 2007 Stock Incentive Plan (the “2007 Plan”) under which 1,000,000 shares were authorized for issuance. The purpose of the 2007 Plan is to promote the long-term growth and profitability of the Company by providing incentives to improve stockholder value and enable the Company to attract, retain and reward the best available persons for positions of substantial responsibility. The 2007 Plan permits the granting of equity awards in the form of incentive stock options, nonqualified stock options, restricted stock, restricted stock units, stock appreciation rights, phantom stock, and performance awards, or in any combination of the foregoing. At the Annual Meetings of Stockholders of Celsion held on June 25, 2010 and June 7, 2012, the stockholders approved amendments to the Plan. The only material difference between the existing Plan and the amended Plan was the number of shares of common stock available for issuance under the amended Plan which was increased by 1,000,000 to a total of 2,000,000 shares in 2010 and by 2,250,000 to a total of 4,250,000 shares in 2012.

Prior to the adoption of the 2007 Plan, the Company adopted two stock plans for directors, officers and employees (one in 2001 and another in 2004) under which 666,667 shares were reserved for future issuance under each of these plans. As these plans have been superseded by the 2007 Plan, any options previously granted which expire, forfeit, or cancel under these plans will be rolled into the 2007 Plan.

The fair values of stock options granted were estimated at the date of grant using the Black-Scholes option pricing model. The Black-Scholes model was originally developed for use in estimating the fair value of traded options, which have different characteristics from Celsion’s stock options. The model is also sensitive to changes in assumptions, which can materially affect the fair value estimate.

The Company used the following assumptions for determining the fair value of options granted under the Black-Scholes option pricing model:

	Nine Months ended September 30,
	2012			2011
Risk-free interest rate	1.60	-	2.97%	2.29	-	2.97%
Expected volatility	80.2	-	82.3%	72.2	-	81.1%
Expected life (in years)	5.0	-	6.25		6.25
Expected forfeiture rate	0.0%	-	7.5%		0.0%
Expected dividend yield		0.0%			0.0%

Expected volatilities utilized in the model are based on historical volatility of the Company’s stock price. The risk free interest rate is derived from values assigned to U.S. Treasury bonds as published in the Wall Street Journal in effect at the time of grant. The model incorporates exercise, pre-vesting and post-vesting forfeiture assumptions based on analysis of historical data. The expected life of the fiscal 2012 and 2011 grants was generated using the simplified method.

A summary of the Company’s stock option and restricted stock awards for nine month period ended September 30, 2012 is as follows:

	Stock Options					Restricted Stock Awards					Weighted Average Contractual Terms of Equity Awards (in years)
Equity Awards	Options Outstanding			Weighted Average Exercise Price		Non-vested Restricted Stock Outstanding			Weighted Average Grant Date Fair Value

Equity awards outstanding at December 31, 2011		3,113,144		$	3.75		54,867		$	3.16

Equity awards granted		623,251		$	2.11		5,544		$	2.10

Equity awards exercised		(38,750	)	$	2.70		(9,557	)	$	2.86

Equity awards forfeited, cancelled or expired		(264,669	)	$	6.80		(6,667	)		2.86

Equity awards outstanding at September 30, 2012		3,432,976		$	3.24		44,167		$	3.13	6.81

Aggregate intrinsic value of outstanding awards at September 30, 2012	$	7,723,556				$	239,385

Equity awards exercisable at September 30, 2012		2,062,954		$	3.74						5.57

Aggregate intrinsic value of awards exercisable at September 30, 2012	$	3,574,674

Total compensation cost related to employee stock options and restricted stock awards amounted to $276,107 and $332,918 for the three months ended September 30, 2012 and 2011, respectively. Total compensation cost related to employee stock options and restricted stock awards amounted to $850,990 and $892,894 for the nine months ended September 30, 2012 and 2011, respectively. No compensation cost related to share-based payments arrangements was capitalized as part of the cost of any asset as of September 30, 2012 or 2011.

As of September 30, 2012, there was $1.8 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements. That cost is expected to be recognized over a weighted-average period of 1.9 years. The weighted average grant-date fair value was $1.48 and $2.62 per share for the options granted during the nine months ended September 30, 2012 and 2011, respectively. The weighted average grant-date fair value was $2.10 and $2.68 for the restricted stock awards granted during the nine months ended September 30, 2012 and 2011, respectively.

Collectively, for all the stock option plans as of September 30, 2012, there were a total of 6,013,334 shares reserved, which were comprised of 3,477,143 equity awards granted and 2,536,191 equity awards available for future issuance.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6406099&loc=d3e25284-112666

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 40
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6418621&loc=d3e17540-113929

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5070-113901

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5047-113901

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6415400&loc=d3e5444-113901

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 14

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 123R
-Paragraph 64, 65, A240
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 93-6
-Paragraph 53
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Note 10. Warrants

9 Months Ended

Sep. 30, 2012

Warrants [Text Block]

Note 10. Warrants

Common Stock Warrants

Following is a summary of all warrant activity for 2012:

Warrants	Number of Warrants Issued			Weighted Average Exercise Price
Warrants outstanding at December 31, 2011		11,627,001		$	3.15

Warrants granted in connection with the Credit Agreement as more fully described in Note 9		51,370		$	2.92

Warrants exercised for common stock		(1,512,110	)		2.58

Warrants outstanding at September 30, 2012		10,166,261		$	3.23

Aggregate intrinsic value of outstanding warrants at September 30, 2012	$	22,232,473

Weighted average remaining contractual terms (years)	4.20

During the third quarter of 2012, the Company received gross proceeds of approximately $3.9 million from the exercise of warrants to purchase 1,512,110 shares of common stock. During the 4th quarter of 2012 and as of the date of this Form 10Q filing, the Company received additional proceeds of approximately $681,000 from the exercise of warrants and options to purchase common stock.

Common Stock Warrant Liability

In September 2009, the Company closed a registered direct offering with a select group of institutional investors that raised gross proceeds of $7.1 million and net proceeds of $6.3 million. In connection with this registered direct offering, the Company issued 2,018,153 shares of its common stock and warrants to purchase 1,009,076 shares of common stock. The warrants have an exercise price of $5.24 per share and are exercisable at any time on or after the six month anniversary of the date of issuance and on or prior to 66 months after the date of issuance. Under the terms of the warrants, upon certain transactions, including a merger, tender offer or sale of all or substantially all of the assets of the Company, each warrant holder may elect to receive a cash payment in exchange for the warrant, in an amount determined by application of the Black-Scholes option valuation model. Accordingly, pursuant to ASC 815.40, Derivative Instruments and Hedging - Contracts in Entity’s Own Equity, the warrants are recorded as a liability and then marked to market each period through the Statement of Operations in other income or expense. At the end of each subsequent quarter, the Company will revalue the fair value of the warrants and the change in fair value will be recorded as a change to the warrant liability and the difference will be recorded through the Statement of Operations in other income or expense.

The fair value of the warrants at September 30, 2012 and December 31, 2011 was $1,417,248 and $166,398, respectively, calculated using the Black-Scholes option-pricing model with the following assumptions:

	September 30, 2012			December 31,2011
Risk-free interest rate		0.62	%		0.83	%
Expected volatility		55.14	%		75.17	%
Expected life (in years)		1.25			1.6
Expected forfeiture rate		0.0	%		0.0	%
Expected dividend yield		0.00	%		0.00	%

As a result of this change in the warrant liability, the Company recorded a non-cash loss of $1.3 million in the nine months ended September 30, 2012. The following is a summary of the changes in the common stock warrant liability for the nine months ended September 30, 2012:

Beginning balance, January 1, 2012	$	166,398
Issuances		-
Loss from the adjustment for the change in fair value included in net loss		1,250,850
Ending balance, September 30, 2012	$	1,417,248

Note 11. Contingent Liabilities and Commitments

9 Months Ended

Sep. 30, 2012

Commitments and Contingencies Disclosure [Text Block]

Note 11. Contingent Liabilities and Commitments

In July 2011, the Company executed a lease (the “Lease”) with Brandywine Operating Partnership, L.P. (Brandywine), a Delaware limited partnership for a 10,870 square foot premises located in Lawrenceville, New Jersey. In October 2011, the Company relocated its offices to Lawrenceville, New Jersey from Columbia, Maryland. The lease has a term of 66 months and provides for 6 months rent free, with the first monthly rent payment of approximately $23,000 due in April 2012. Also, as required by the Lease, the Company provided Brandywine with an irrevocable and unconditional standby letter of credit for $250,000, which the Company secured with an escrow deposit at its banking institution of this same amount. The standby letter of credit will be reduced by $50,000 on each of the 19th, 31st and 43rd months from the initial term, with the remaining $100,000 amount remaining until the Lease Term has expired.

- Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6449706&loc=d3e16207-108621

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 460
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=6398077&loc=d3e12565-110249

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6952336&loc=d3e14435-108349

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.25)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6394976&loc=d3e25287-109308

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Interpretation (FIN)
-Number 14
-Paragraph 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 9, 10, 11, 12
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Note 12. Technology Development and Licensing Agreements

9 Months Ended

Sep. 30, 2012

Licensing Transaction [Text Block]

Note 12. Technology Development and Licensing Agreements

On May 7, 2012 the Company announced the signing of a long term commercial supply agreement with Zhejiang Hisun Pharmaceutical Co. Ltd. (Hisun) for the production of ThermoDox® in the China territory. In accordance with the terms of the agreement, Hisun will be responsible for providing all of the technical and regulatory support services, including the costs of all technical transfer, registrational and bioequivalence studies, technical transfer costs, Celsion consultative support costs and the purchase of any necessary equipment and additional facility costs necessary to support capacity requirements for the manufacture of ThermoDox®. Celsion will repay Hisun for the aggregate amount of these development costs and fees commencing on the successful completion of three registrational batches of ThermoDox®. Hisun is also obligated to certain performance requirements under the agreement. The agreement will initially be limited to a percentage of the production requirements of ThermoDox® in the China territory with Hisun retaining an option for additional global supply after local regulatory approval in the China territory. In addition, Hisun will collaborate with Celsion around the regulatory approval activities for ThermoDox® with the China State Food and Drug Administration (SFDA). As of September 30, 2012, the Company has incurred approximately $95,000 in costs to be reimbursed to Hisun.

On December 5, 2008, we entered into a development, product supply and commercialization agreement with Yakult Honsha Co. (the Yakult Agreement) under which Yakult was granted the exclusive right to commercialize and market ThermoDox® for the Japanese market. We were paid a $2.5 million up-front licensing fee and may receive additional payments from Yakult upon receipt of marketing approval by the Japanese Ministry of Health, Labor and Welfare as well as upon the achievement of certain levels of sales and approval for new indications. Under the Yakult Agreement, we will receive double digit escalating royalties on the sale of ThermoDox® in Japan, when and if any such sales occur and we also will be the exclusive supplier of ThermoDox® to Yakult. Concurrent with a convertible preferred stock equity financing in January 2011, we amended the Yakult Agreement to provide for up to $4.0 million in accelerated partial payments to us on a drug approval milestone. The terms of the Yakult Agreement provided for the payment to us of $2.0 million upon the closing of the preferred equity financing. The second $2.0 million was conditioned upon the resumption of enrollment of Japanese patients in the Japan cohort of the HEAT study, which has not been resumed. In consideration of the $2.0 million accelerated milestone payment from Yakult, we have agreed to reduce future drug approval milestone payments by approximately twenty percent (20%). All other milestone payments are unaffected.

Note 5. Investment Securities - Available For Sale (Tables)

9 Months Ended

Sep. 30, 2012

Available-For-Sale Securities at Fair Value [Table Text Block]

Investment securities - available for sale - at fair value	September 30, 2012		December 31, 2011

Bonds - corporate issuances	$	14,091,590	$	10,157,160
Equity securities		137,591		–
Total short-term investments, available for sale	$	14,229,181	$	10,157,160

Available-for-sale Securities [Table Text Block]

	September 30, 2012				December 31, 2011
	Cost		Fair Value		Cost		Fair Value
Short-term investments
Bonds- corporate issuances	$	14,252,114	$	14,091,590	$	10,325,487	$	10,157,160
Equity securities		108,373		137,591		108,373		–
Total	$	14,360,487	$	14,229,181	$	10,433,860	$	10,157,160

Bond maturities
Within 3 months	$	6,084,600	$	6,010,500	$	5,128,560	$	5,036,920
Between 3-12 months		8,167,514		8,081,090		5,196,927		5,120,240
Total	$	14,252,114	$	14,091,590	$	10,325,487	$	10,157,160

Available-for-sale Securities, Continuous Unrealized Loss Position, Fair Value [Table Text Block]

	September 30, 2012
	Less than 12 months					12 months or Longer				Total
Description of Securities	Fair Value		Gross Unrealized Holding Losses			Fair Value		Gross Unrealized Holding Gains		Fair Value		Gross Unrealized Holding (Losses) Gains

Available for Sale
Bonds – corporate issuances	$	14,091,590	$	(160,524	)	$	–	$	–	$	14,091,590	$	(160,524	)
Equity securities		–		–			137,591		29,218		137,591		29,218
	$	14,091,590	$	(160,524	)	$	137,591	$	29,218	$	14,229,181	$	(131,306	)

	December 31, 2011
	Less than 12 months					12 months or Longer					Total
	Fair Value		Gross Unrealized Holding Losses			Fair Value		Gross Unrealized Holding Losses			Fair Value		Gross Unrealized Holding Losses
Available for Sale
Bonds – corporate issuances	$	10,157,160	$	(168,327	)	$	–	$	–		$	10,157,160	$	(168,327	)
Equity securities		–		(93,924	)		–		(14,449	)		–		(108,373	)
	$	10,157,160	$	(262,251	)	$	–	$	(14,449	)	$	10,157,160	$	(276,700	)

Investment Income [Table Text Block]

	Three Months Ended September 30,					Nine Months Ended September 30,
	2012			2011		2012				2011
Interest and dividend income	$	115,449		$	26,347		$	380,034			$	26,911
Realized losses		(121,030	)		–			(318,206	)			–
	$	(5,581	)	$	26,347		$	61,828			$	26,911

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27337-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27198-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 19, 20, 21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 17
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-1
-Paragraph 21
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

- Definition

Tabular disclosure of investment income derived from investments in debt and equity securities consisting of interest income earned from investments in debt securities and on cash and cash equivalents, dividend income from investments in equity securities, and income or expense derived from the amortization of investment related discounts or premiums, respectively. This item does not include realized or unrealized gains or losses on the sale or holding of investments in debt and equity securities required to be included in earnings for the period or for other than temporary losses related to investments in debt and equity securities which are included in realized losses in the period recognized.

+ References + Details

Note 6. Fair Value of Measurements (Tables)

9 Months Ended

Sep. 30, 2012

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]

	Total Fair Value on the Balance Sheet		Quoted Prices In Active Markets For Identical Assets/Liabilities(Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Assets:
As of September 30, 2012
Short-term investments available for sale
Bonds – corporate issuances	$	14,091,590	$	14,091,590	$	−	$	−
Equity Securities		137,591		–		–		137,591

As of December 31, 2011
Short-term investments available for sale
Bonds – corporate issuances	$	10,157,160	$	10,157,160	$	−	$	−
Equity Securities		–		–		–		–

Liabilities:
As of September 30, 2012
Common stock warrant liability	$	1,417,248	$	−	$	−	$	1,417,248

As of December 31, 2011
Common stock warrant liability	$	166,398	$	−	$	−	$	166,398

Note 7. Other Accrued Liabilities (Tables)

9 Months Ended

Sep. 30, 2012

Schedule of Accrued Liabilities [Table Text Block]

	September 30, 2012		December 31, 2011
Amounts due to Contract Research Organizations and other contractual agreements	$	2,256,514	$	1,234,875
Accrued payroll and related benefits		322,713		632,425
Accrued professional fees		108,653		137,400
Other		27,629		27,234
Total	$	2,715,509	$	2,031,934

Note 8. Note Payable (Tables)

9 Months Ended

Sep. 30, 2012

Schedule of Maturities of Long-term Debt [Table Text Block]

	Credit Agreement
For the year ending September 30:
2013	$	886,616
2014		1,936,586
2015		2,176,798
	$	5,000,000

Note 9. Stock Based Compensation (Tables)

9 Months Ended

Sep. 30, 2012

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Nine Months ended September 30,
	2012			2011
Risk-free interest rate	1.60	-	2.97%	2.29	-	2.97%
Expected volatility	80.2	-	82.3%	72.2	-	81.1%
Expected life (in years)	5.0	-	6.25		6.25
Expected forfeiture rate	0.0%	-	7.5%		0.0%
Expected dividend yield		0.0%			0.0%

Schedule of Shar-based Compensation, Stock Options and Restricted Stock Awards, Activity [Table Text Block]

	Stock Options					Restricted Stock Awards					Weighted Average Contractual Terms of Equity Awards (in years)
Equity Awards	Options Outstanding			Weighted Average Exercise Price		Non-vested Restricted Stock Outstanding			Weighted Average Grant Date Fair Value

Equity awards outstanding at December 31, 2011		3,113,144		$	3.75		54,867		$	3.16

Equity awards granted		623,251		$	2.11		5,544		$	2.10

Equity awards exercised		(38,750	)	$	2.70		(9,557	)	$	2.86

Equity awards forfeited, cancelled or expired		(264,669	)	$	6.80		(6,667	)		2.86

Equity awards outstanding at September 30, 2012		3,432,976		$	3.24		44,167		$	3.13	6.81

Aggregate intrinsic value of outstanding awards at September 30, 2012	$	7,723,556				$	239,385

Equity awards exercisable at September 30, 2012		2,062,954		$	3.74						5.57

Aggregate intrinsic value of awards exercisable at September 30, 2012	$	3,574,674

Note 10. Warrants (Tables)

9 Months Ended

Sep. 30, 2012

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

Warrants	Number of Warrants Issued			Weighted Average Exercise Price
Warrants outstanding at December 31, 2011		11,627,001		$	3.15

Warrants granted in connection with the Credit Agreement as more fully described in Note 9		51,370		$	2.92

Warrants exercised for common stock		(1,512,110	)		2.58

Warrants outstanding at September 30, 2012		10,166,261		$	3.23

Aggregate intrinsic value of outstanding warrants at September 30, 2012	$	22,232,473

Weighted average remaining contractual terms (years)	4.20

	September 30, 2012			December 31,2011
Risk-free interest rate		0.62	%		0.83	%
Expected volatility		55.14	%		75.17	%
Expected life (in years)		1.25			1.6
Expected forfeiture rate		0.0	%		0.0	%
Expected dividend yield		0.00	%		0.00	%

Schedule of Common Stock Warranty Liability [Table Text Block]

Beginning balance, January 1, 2012	$	166,398
Issuances		-
Loss from the adjustment for the change in fair value included in net loss		1,250,850
Ending balance, September 30, 2012	$	1,417,248

Note 4. Net Loss Per Common Share (Detail) - shares	9 Months Ended
Note 4. Net Loss Per Common Share (Detail) - shares	Sep. 30, 2012	Sep. 30, 2011
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	13,643,404	11,492,716

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Antidilution
-URI http://asc.fasb.org/extlink&oid=6505113

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Diluted Earnings Per Share
-URI http://asc.fasb.org/extlink&oid=6510752

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Contingent Stock Agreement
-URI http://asc.fasb.org/extlink&oid=6508534

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 40
-Subparagraph c
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 13, 14
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 171
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Note 5. Investment Securities - Available For Sale (Detail) - USD ($)	Sep. 30, 2012	Dec. 31, 2011
Short-term Investments	$ 14,229,181	$ 10,157,160

Note 5. Investment Securities - Available For Sale (Detail) - Short-term Investment at Fair Value - USD ($)	Sep. 30, 2012	Dec. 31, 2011
Corporate Debt Securities [Member]
Short-term investments, available for sale - at fair value	$ 14,091,590	$ 10,157,160
Equity Securities [Member]
Short-term investments, available for sale - at fair value	137,591
Short-term investments, available for sale - at fair value	$ 14,229,181	$ 10,157,160

Note 5. Investment Securities - Available For Sale (Detail) - Short-term Investment by Bond Maturities - USD ($)	Sep. 30, 2012	Dec. 31, 2011
Corporate Debt Securities [Member]
Short-term investments
Cost	$ 14,252,114	$ 10,325,487
Fair value	14,091,590	10,157,160
Total	14,252,114	10,325,487
Total	14,091,590	10,157,160
Equity Securities [Member]
Short-term investments
Cost	108,373	108,373
Fair value	137,591
Total	108,373	108,373
Total	137,591
Within 3 Months [Member]
Bond maturities
Cost	6,084,600	5,128,560
Fair value	6,010,500	5,036,920
Total	6,084,600	5,128,560
Between 3-12 Months [Member]
Bond maturities
Cost	8,167,514	5,196,927
Fair value	8,081,090	5,120,240
Total	8,167,514	5,196,927
Bond maturities [Member]
Short-term investments
Total	14,091,590	10,157,160
Bond maturities
Cost	14,252,114	10,325,487
Total	14,252,114	10,325,487
Cost	14,360,487	10,433,860
Total	14,360,487	10,433,860
Total	$ 14,229,181	$ 10,157,160

Note 5. Investment Securities - Available For Sale (Detail) - Short-term Investment - Continuous Unrealized Loss Position - USD ($)	Sep. 30, 2012	Dec. 31, 2011
Debt Securities [Member]
Available for Sale
Fair Value - Less than 12 months	$ 14,091,590	$ 10,157,160
Gross Unrealized Holding Losses - Less than 12 months	(160,524)	(168,327)
Fair Value - Total	14,091,590	10,157,160
Gross Unrealized Holding (Losses) Gains - Total	(160,524)	(168,327)
Equity Securities [Member]
Available for Sale
Gross Unrealized Holding Losses - Less than 12 months		(93,924)
Fair Value - Total	137,591
Gross Unrealized Holding (Losses) Gains - Total	29,218	(108,373)
Gross Unrealized Holding Gains - 12 months or Longer	29,218	(14,449)
Fair Value - 12 months or Longer	137,591
Fair Value - Less than 12 months	14,091,590	10,157,160
Gross Unrealized Holding Losses - Less than 12 months	(160,524)	(262,251)
Fair Value - Total	14,229,181	10,157,160
Gross Unrealized Holding (Losses) Gains - Total	(131,306)	(276,700)
Gross Unrealized Holding Gains - 12 months or Longer	29,218	$ (14,449)
Fair Value - 12 months or Longer	$ 137,591

Note 5. Investment Securities - Available For Sale (Detail) - Investment Income - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011
Interest and dividend income	$ 115,449	$ 26,347	$ 380,034	$ 26,911
Realized losses	(121,030)		(318,206)
	$ (5,581)	$ 26,347	$ 61,828	$ 26,911

Note 6. Fair Value of Measurements (Detail)	9 Months Ended
Note 6. Fair Value of Measurements (Detail)	Sep. 30, 2012
Fair Value, Assets and Liabilities, Transfer Between Level 1 and Level 2, Level 3 Transfer In or Out, Description	There were no transfers of assets or liabilities between Level 1 and Level 2 and no transfers in or out of Level 3 during the nine month period ended September 30, 2012.

Note 6. Fair Value of Measurements (Detail) - Assets and Liabilities at Fair Value on a Recurring Basis - USD ($)	Sep. 30, 2012	Dec. 31, 2011
Corporate Debt Securities [Member] \| Fair Value, Inputs, Level 1 [Member]
Short-term investments available for sale
Fair value on the balance sheet	$ 14,091,590	$ 10,157,160
Corporate Debt Securities [Member]
Short-term investments available for sale
Fair value on the balance sheet	14,091,590	10,157,160
Equity Securities [Member] \| Fair Value, Inputs, Level 3 [Member]
Short-term investments available for sale
Fair value on the balance sheet	137,591
Equity Securities [Member]
Short-term investments available for sale
Fair value on the balance sheet	137,591
Fair Value, Inputs, Level 3 [Member]
As of September 30, 2012
Fair value on the balance sheet	1,417,248	166,398
Fair value on the balance sheet	$ 1,417,248	$ 166,398

- Definition

This element represents the portion of the balance sheet assertion valued at fair value by the entity whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. This item represents Available-for-sale Securities which consist of all investments in certain debt and equity securities neither classified as trading or held-to-maturity securities. A debt security represents a creditor relationship with an enterprise. Debt securities include, among other items, US Treasury securities, US government securities, municipal securities, corporate bonds, convertible debt, commercial paper, and all securitized debt instruments. An equity security represents an ownership interest in an enterprise or the right to acquire or dispose of an ownership interest in an enterprise at fixed or determinable prices. Equity securities include, among other things, common stock, certain preferred stock, warrant rights, call options, and put options, but do not include convertible debt. An entity may opt to provide the reader with additional narrative text to better understand the nature of investments in debt and equity securities which are categorized as Available-for-sale.

+ References + Details

Note 7. Other Accrued Liabilities (Detail) - Other Accrued Liabilities - USD ($)	Sep. 30, 2012	Dec. 31, 2011
Amounts due to Contract Research Organizations and other contractual agreements	$ 2,256,514	$ 1,234,875
Accrued payroll and related benefits	322,713	632,425
Accrued professional fees	108,653	137,400
Other	27,629	27,234
Total	$ 2,715,509	$ 2,031,934

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References + Details

Note 8. Note Payable (Detail) - USD ($)	3 Months Ended		6 Months Ended	9 Months Ended	28 Months Ended	31 Months Ended
Note 8. Note Payable (Detail) - USD ($)	Sep. 30, 2012	Dec. 31, 2011	Jun. 30, 2012	Sep. 30, 2012	Feb. 28, 2014	Apr. 30, 2012	Jun. 27, 2012	Nov. 30, 2011	Oct. 31, 2009
October 2009 Capital Lease [Member]
Capital Leased Assets, Gross									$ 288,200
Debt Instrument, Periodic Payment						$ 11,654
Payments for (Proceeds from) Loans and Leases			$ 58,270
Capital Lease Obligations	$ 85,618			$ 85,618
November 2011 Capital Lease [Member]
Capital Leased Assets, Gross								$ 144,448
Debt Instrument, Periodic Payment					$ 5,651
Payments for (Proceeds from) Loans and Leases				50,863
Warrant [Member]
Deferred Finance Costs, Net	$ 73,654			$ 73,654
Term A Loan [Member]
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$ 2.92			$ 2.92
Credit Agreement [Member]
Fair Value Assumptions, Expected Volatility Rate				74.30%
Fair Value Assumptions, Risk Free Interest Rate				1.10%
Fair Value Assumptions, Expected Term				3 years 6 months
Line of Credit Facility, Maximum Borrowing Capacity							$ 10,000,000
Loan Tranche Amount							$ 5,000,000
Debt Instrument, Interest Rate, Stated Percentage							11.75%
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Maximum				11.75%
Debt Instrument, Basis Spread on Variable Rate	0.47%			0.47%
Debt Instrument, Interest Rate, Stated Percentage Rate Range, Minimum				11.28%
Note Stock Conversion Rate				3.00%
Common Stock, Par or Stated Value Per Share (in Dollars per share)	$ 0.01	$ 0.01		$ 0.01
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares)				51,370
Warrants Issued Expiration Period				7 years
Deferred Finance Costs, Net	$ 21,605			$ 21,605
Fair Value Assumptions, Expected Volatility Rate		75.17%		55.14%
Fair Value Assumptions, Risk Free Interest Rate		0.83%		0.62%
Fair Value Assumptions, Expected Term		1 year 219 days		1 year 3 months
Fair Value Assumptions, Exercise Price (in Dollars per share)	$ 2.80			$ 2.80
Increase (Decrease) in Prepaid Expense				$ 207,207
Line of Credit Facility, Periodic Payment, Interest	$ 146,875

Note 8. Note Payable (Detail) - Future Principal Payments Due on the Credit Agreement	Sep. 30, 2012 USD ($)
2013	$ 886,616
2014	1,936,586
2015	2,176,798
	$ 5,000,000

Note 9. Stock Based Compensation (Detail) - USD ($)			3 Months Ended		9 Months Ended		57 Months Ended
Note 9. Stock Based Compensation (Detail) - USD ($)	Jun. 25, 2012	Jun. 25, 2010	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012	Dec. 31, 2007	Dec. 31, 2006
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term					10 years
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	2,250,000	2,000,000	6,013,334		6,013,334		6,013,334	1,000,000	666,667
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized	4,250,000	1,000,000
Share-based Compensation (in Dollars)			$ 276,107	$ 332,918	$ 850,990	$ 892,894
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized (in Dollars)			$ 1,800,000		$ 1,800,000		$ 1,800,000
Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition					1 year 328 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)					$ 1.48	$ 2.62
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value (in Dollars per share)					$ 2.10	$ 2.68
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					623,251		3,477,143
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant			2,536,191		2,536,191		2,536,191

Note 9. Stock Based Compensation (Detail) - Fair Value of Option Assumptions	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Minimum [Member]
Risk-free interest rate	1.60%	2.29%
Expected volatility	80.20%	72.20%
Expected life (in years)	5 years
Expected forfeiture rate	0.00%
Maximum [Member]
Risk-free interest rate	2.97%	2.97%
Expected volatility	82.30%	81.10%
Expected life (in years)	6 years 3 months
Expected forfeiture rate	7.50%

Note 9. Stock Based Compensation (Detail) - Stock Option and Restricted Stock Awards - USD ($)	9 Months Ended		57 Months Ended
	Sep. 30, 2012	Sep. 30, 2011	Sep. 30, 2012
Equity awards outstanding at December 31, 2011	3,113,144
Equity awards outstanding at December 31, 2011 (in Dollars per share)	$ 3.75
Equity awards outstanding at December 31, 2011	54,867
Equity awards outstanding at December 31, 2011 (in Dollars per share)	$ 3.16
Equity awards granted	623,251		3,477,143
Equity awards granted (in Dollars per share)	$ 2.11
Equity awards granted	5,544
Equity awards granted (in Dollars per share)	$ 2.10	$ 2.68
Equity awards exercised	(9,557)
Equity awards exercised (in Dollars per share)	$ 2.86
Equity awards exercised	(38,750)
Equity awards exercised (in Dollars per share)	$ 2.70
Equity awards forfeited, cancelled or expired	(264,669)
Equity awards forfeited, cancelled or expired (in Dollars per share)	$ 6.80
Equity awards forfeited, cancelled or expired	(6,667)
Equity awards forfeited, cancelled or expired (in Dollars per share)	$ 2.86
Equity awards outstanding at September 30, 2012	3,432,976		3,432,976
Equity awards outstanding at September 30, 2012 (in Dollars per share)	$ 3.24		$ 3.24
Equity awards outstanding at September 30, 2012	44,167		44,167
Equity awards outstanding at September 30, 2012 (in Dollars per share)	$ 3.13		$ 3.13
Equity awards outstanding at September 30, 2012	6 years 295 days		6 years 295 days
Aggregate intrinsic value of outstanding awards at September 30, 2012 (in Dollars)	$ 7,723,556		$ 7,723,556
Aggregate intrinsic value of outstanding awards at September 30, 2012 (in Dollars)	$ 239,385		$ 239,385
Equity awards exercisable at September 30, 2012	2,062,954		2,062,954
Equity awards exercisable at September 30, 2012 (in Dollars per share)	$ 3.74		$ 3.74
Equity awards exercisable at September 30, 2012	5 years 208 days		5 years 208 days
Aggregate intrinsic value of awards exercisable at September 30, 2012 (in Dollars)	$ 3,574,674		$ 3,574,674

Note 10. Warrants (Detail) - USD ($)	1 Months Ended	3 Months Ended		9 Months Ended
Note 10. Warrants (Detail) - USD ($)	Sep. 30, 2009	Dec. 31, 2012	Sep. 30, 2012	Sep. 30, 2012	Sep. 30, 2011	Dec. 31, 2011
Warrant Liability [Member]
Change in Fair Value of Common Stock Warrant Liability				$ 1,300,000
Proceeds from Warrant Exercises			$ 3,900,000	$ 3,823,690	$ 394,336
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares)			1,512,110	1,512,110
Proceeds from Exercise of Warrants and Options		$ 681,000
Proceeds from Issuance of Warrants	$ 7,100,000
Proceeds from Issuance of Warrants, Net	$ 6,300,000
Common Stock and Warrants Issued, Shares (in Shares)	2,018,153
Common Stock, Shares, Issued (in Shares)	1,009,076		35,459,494	35,459,494		33,899,057
Investment Warrants, Exercise Price (in Dollars per share)	$ 5.24
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms	66 months			4 years 73 days
Common Stock Warrant Liability			$ 1,417,248	$ 1,417,248		$ 166,398
Change in Fair Value of Common Stock Warrant Liability				$ 1,250,850	$ 42,482

Note 10. Warrants (Detail) - Summary of Warrant Activity	1 Months Ended	9 Months Ended
	Sep. 30, 2009	Sep. 30, 2012 $ / shares $ / item shares
Warrant [Member]
Warrants granted in connection with the Credit Agreement as more fully described in Note 9		51,370
Warrants granted in connection with the Credit Agreement as more fully described in Note 9 (in Dollars per share) \| $ / shares		$ 2.92
Number of Warrants Issued		11,627,001
Weighted Average Exercise Price (in Dollars per Item) \| $ / item		3.15
Aggregate intrinsic value of outstanding warrants at September 30, 2012 (in Dollars per share) \| $ / shares		$ 22,232,473
Weighted average remaining contractual terms (years)	66 months	4 years 73 days
Warrants granted in connection with the Credit Agreement as more fully described in Note 9		5,544
Warrants exercised for common stock		(1,512,110)
Warrants exercised for common stock (in Dollars per share) \| $ / shares		$ 2.58
Number of Warrants Issued		10,166,261
Weighted Average Exercise Price (in Dollars per Item) \| $ / item		3.23

- Definition

The intrinsic value of nonvested awards on equity-based plans excluding option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, revenue or profit achievement stock award plan) for which the employer is contingently obligated to issue equity instruments or transfer assets to an employee who has not yet satisfied service or performance criteria necessary to gain title to proceeds from the sale of the award or underlying shares or units, as calculated by applying the disclosed pricing methodology.

+ References + Details

Note 10. Warrants (Detail) - Fair Value of Warrants Assumptions	3 Months Ended	9 Months Ended
	Dec. 31, 2011	Sep. 30, 2012
Risk-free interest rate	0.83%	0.62%
Expected volatility	75.17%	55.14%
Expected life (in years)	1 year 219 days	1 year 3 months
Expected forfeiture rate	0.00%	0.00%
Expected dividend yield	0.00%	0.00%

Note 10. Warrants (Detail) - Common Stock Warrant Liability - USD ($)	9 Months Ended
	Sep. 30, 2012	Sep. 30, 2011
Beginning balance, January 1, 2012	$ 166,398
Loss from the adjustment for the change in fair value included in net loss	1,250,850	$ 42,482
Ending balance, September 30, 2012	$ 1,417,248

Note 11. Contingent Liabilities and Commitments (Detail)	1 Months Ended	9 Months Ended
	Apr. 30, 2012 USD ($)	Sep. 30, 2012 USD ($)	Jul. 31, 2011 ft²
Area of Real Estate Property (in Square feet) \| ft²			10,870
Lease Term		66 months
Number of Months in Which Free Rent is Provided		6 months
Payments for Rent	$ 23,000
Letter of Credit Required by Lease, Face Amount		$ 250,000
Reduction Amount on Letter of Credit Required by Lease		50,000
Lette of Credit Amount Remaining Until Lease Term Expires		$ 100,000

Note 12. Technology Development and Licensing Agreements (Detail) - USD ($)		1 Months Ended
	Dec. 05, 2008	Jan. 31, 2011	Sep. 30, 2012	Dec. 31, 2011
Hisun [Member]
Other Accrued Liabilities, Current			$ 95,000
Convertible Preferred Stock [Member]
Proceeds from Issuance of Convertible Preferred Stock		$ 2,000,000
Yakult Agreement [Member]
Proceeds from Issuance of Convertible Preferred Stock		2,000,000
Other Accrued Liabilities, Current			$ 2,715,509	$ 2,031,934
Proceeds from License Fees Received	$ 2,500,000
Proceeds from Issuance of Convertible Preferred Stock		$ 4,000,000
Reduction in Milestone Payments		20.00%

- Definition

+ References + Details